# Mylan

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/mylan/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | former pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320316473 |
| ROR ID | https://ror.org/04nsw4151 |
| Works | 2,978 |

## Funder papers

- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-continued-weekly-subcutaneous-semaglutide-vs-placebo-on-weight-loss/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Quality of Life and Burden of Moderate-to-Severe Atopic Dermatitis in Adult Patients Within the Asia–Pacific Region: A Cross-sectional Survey](https://scholariq.org/papers/quality-of-life-and-burden-of-moderate-to-severe-atopic-dermatitis-in-adult/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.